[ad_1]
FILE PHOTO: The logo of Teva Pharmaceutical Industries is visible at a press conference given by its CEO, Kare Schultz, to discuss the company's outlook for 2019 in Tel Aviv, Israel on February 19, 2019. REUTERS / Amir Cohen
(Reuters) – Generic drug maker Teva Pharmaceutical Industries Ltd. received Friday clearance from the Food and Drug Administration (FDA) to market its generic nasal spray for the treatment of opioid overdose, announced the health regulatory officer.
This is the first approval of a generic nasal spray with naloxone intended for use in a community setting by individuals without medical training, the FDA said in a statement.
Nearly 400,000 people died of an opioid overdose between 1999 and 2017, the regulator said, citing data from the Centers for Disease Control and Prevention.
The FDA had tentatively approved the generic Naloxone Teva Nasal Spray in June of last year.
Ankit Ajmera's report to Bengaluru; Edited by Chizu Nomiyama
[ad_2]
Source link